Cannabinoid-Based Drugs Seek New High, Part II
Developers Anticipate Additional Approvals after FDA Nod for Epidiolex
Single-Cell Cloning Remains a Challenge
Evolving Technologies Help Make It Easier to Meet Regulatory Requirements
Pushing the Right Buttons
Improving Efficacy of Therapeutic DNA Vectors
Cell Line Validation in Biomanufacturing
Confirming Identity, Purity, Sterility, and Functionality of Cell Lines Helps Keep Patients Safe
Colette Cote Ph.D.
Colette Côté, Ph.D., is principal scientist, head of next-generation sequencing and bioinformatics, development services at the BioReliance® portfolio of MilliporeSigma.